VanEck Vectors Generic Drugs ETF
GNRX
GNRX was delisted on the 4th of April, 2019.
3 hedge funds and large institutions have $414K invested in VanEck Vectors Generic Drugs ETF in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
212% more capital invested
Capital invested by funds: $133K → $414K (+$281K)
200% more funds holding
Funds holding: 1 → 3 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$255K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $257K | +$255K | +11,614 | New |
|
|
APA
2
American Portfolios Advisors
Holbrook,
New York
| $142K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $15K | +$14.5K | +660 | New |
|
GNRX Hedge Fund Activity: Q1 2019 in Review
3 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q1 2019, worth a combined $414K — up 212% from $133K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GNRX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $255K.
- 3 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q1 2019, up from 1 in Q4 2018.
- Funds reported $414K of VanEck Vectors Generic Drugs ETF stock for Q1 2019, up 212% quarter-over-quarter.
- 2 funds opened new VanEck Vectors Generic Drugs ETF positions in Q1 2019 and 0 closed out, a net change of +2 holders.
- The largest VanEck Vectors Generic Drugs ETF buyer in Q1 2019 was Susquehanna International Group, an estimated $255K added.
Based on aggregated 13F filings for Q1 2019.